Shaun G. Goodman

Research interests

Publications

• Empagliflozin after Acute Myocardial Infarction

  New England Journal of Medicine · 2024 · https://doi.org/10.1056/nejmoa2314051

• Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab

  Circulation · 2022 · https://doi.org/10.1161/circulationaha.121.057807

• Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab

  Circulation · 2022 · https://doi.org/10.1161/circulationaha.121.057807

• Survival After Invasive or Conservative Management of Stable Coronary Disease

  Circulation · 2022 · https://doi.org/10.1161/circulationaha.122.062714

• Survival After Invasive or Conservative Management of Stable Coronary Disease

  Circulation · 2022 · https://doi.org/10.1161/circulationaha.122.062714

• Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol

  Journal of the American College of Cardiology · 2021 · https://doi.org/10.1016/j.jacc.2021.04.102

• Initial Invasive or Conservative Strategy for Stable Coronary Disease

  New England Journal of Medicine · 2020 · https://doi.org/10.1056/nejmoa1915922

• Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy on Ischemic Outcomes After Percutaneous Coronary Intervention

  JAMA · 2020 · https://doi.org/10.1001/jama.2020.12443

• Effect of Empagliflozin on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease

  Circulation · 2019 · https://doi.org/10.1161/circulationaha.119.042375

• Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation

  New England Journal of Medicine · 2019 · 10.1056/nejmoa1817083

• Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial

  The Lancet · 2018 · https://doi.org/10.1016/s0140-6736(18)32261-x

• Prehospital Ticagrelor in ST-Segment Elevation Myocardial Infarction

  New England Journal of Medicine · 2014 · https://doi.org/10.1056/nejmoa1407024

• Factors Associated With Major Bleeding Events

  Journal of the American College of Cardiology · 2013 · https://doi.org/10.1016/j.jacc.2013.11.013

• Prasugrel versus Clopidogrel for Acute Coronary Syndromes without Revascularization

  New England Journal of Medicine · 2012 · 10.1056/nejmoa1205512

• Intravenous Platelet Blockade with Cangrelor during PCI

  New England Journal of Medicine · 2009 · https://doi.org/10.1056/nejmoa0908629

• Platelet Inhibition with Cangrelor in Patients Undergoing PCI

  New England Journal of Medicine · 2009 · https://doi.org/10.1056/nejmoa0908628

• Decline in Rates of Death and Heart Failure in Acute Coronary Syndromes, 1999-2006

  JAMA · 2007 · 10.1001/jama.297.17.1892

• Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE)

  BMJ · 2006 · 10.1136/bmj.38985.646481.55

• Intervention in acute coronary syndromes: do patients undergo intervention on the basis of their risk characteristics? The Global Registry of Acute Coronary Events (GRACE)

  Heart · 2006 · https://doi.org/10.1136/hrt.2005.084830

• A Validated Prediction Model for All Forms of Acute Coronary Syndrome

  JAMA · 2004 · 10.1001/jama.291.22.2727

• Adherence to evidence-based therapies after discharge for acute coronary syndromes: an ongoing prospective, observational study

  The American Journal of Medicine · 2004 · https://doi.org/10.1016/j.amjmed.2003.12.041

• Randomized trial of low molecular weight heparin (enoxaparin) versus unfractionated heparin for unstable coronary artery disease∗∗∗∗A list of participating ESSENCE Study Group investigators may be found in N Engl J Med 1997;337:447–52.

  Journal of the American College of Cardiology · 2000 · https://doi.org/10.1016/s0735-1097(00)00808-1

Current projects

No projects listed.